Okihiro A, et al. - A review was performed on the biologic database of pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies for neoplasms, patient demographic information and rheumatologic treatment course. A low malignancy rate was noted by the experts. More than half of the neoplasms identified were rare and unusual in the pediatric population. In patients with juvenile idiopathic arthritis (JIA) treated with biologic therapy, the 5-year malignancy-free probability was 97%. As part of the safety monitoring, long-term screening for rare neoplasms was noted to be important for any pediatric rheumatology patient receiving anti-TNF therapy.